Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer

Running, not enrolling · Phase 2

Conditions studied: Cancer Neck, Larynx Cancer, Glottis Tumor

In brief

This is a multicentrer, randomized Bayesian Phase II trial for patients with early stage (T1N0) glottic squamous cell carcinoma treated with radical radiotherapy. The primary objective is to assess the non-inferiority of local control achieved with vocal-cord only radiotherapy (VC-RT) compared to complete larynx radiotherapy (CL-RT) in T1N0 glottic laryngeal squamous cell cancer, measured at 2-years after treatment. Secondary outcomes include overall survival, as well as voice impairment, dysphagia and quality of life, measured respectively by the voice handicap index -10 (VHI-10), the MD Anderson Dysphagia Inventory (MDADI) and the MD Anderson Symptom Inventory- Head and Neck module (MDASI-HN). Patients will be randomized in a 1:3 ratio to CL-RT (39 patients) and VC-RT (116 patients) arms. There will be stratification by tumor stage (T1a/T1b) and by institution. An interim analysis is planned after the first 55 patients enrolled on the experimental arm have a 6-month follow-up.

Key facts

Study ID

NCT03759431

Run by

Centre hospitalier de l'Université de Montréal (CHUM)

People needed

155

Starts

2018-10-11

Expected to finish

2026-12-12

Last updated by the study team

2025-03-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage T1a-b N0 of the true vocal cords planned for definitive RT
• Patient not candidate for laser surgery or declined laser surgery
• Biopsy-confirmed squamous cell carcinoma, including verrucous carcinoma
• Eastern Cooperative Oncology Group performance status 0-2
• Ability to provide written informed consent.

You may not qualify if…

• Previous irradiation of the head and neck (HNC) region
• Pregnancy or breastfeeding
• Any medical condition that represents, in the opinion of the investigator, a contraindication to radiotherapy or would prevent follow-up after radiotherapy.
• Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years.

Where it is running

• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• London Health Sciences Centre — London, Ontario, Canada
• Centre Hospitalier de l'Université de Montréal — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.